Nancy Stagliano has a very clear idea of how to plot a course for True North. Eighteen months ago the biotech CEO raised $30 million for iPierian and split its assets with the newborn True North Therapeutics. Seven months later Bristol-Myers Squibb snapped up a reorganized iPierian in a $725 million deal. Then in swift succession Stagliano raised new funds, beefed up her staff with a key hire and is now banking $35 million in a fresh venture round that will take True North into the clinic with its lead therapy for rare diseases while positioning its follow-up program for human studies.
About 7 months after splitting her company into two biotechs, CEO Nancy Stagliano has sold iPierian and its preclinical foray against neurodegenerative diseases--including Alzheimer's--to Bristol-Myers Squibb for $175 million down and up to $550 million in milestones.
No one ever climbed the industry ladder without getting some help along the way. And for women, including many of the accomplished top performers in this group, that can be especially important....
After taking the helm and pointing South San Francisco-based iPierian in a new direction, CEO Nancy Stagliano today unveiled a $30 million venture round designed to get her crew into the clinic with a lead antibody program, while a separate project is being spun out into a new biotech that she will also direct.
The biotech announced this morning that it will use its expertise in developing disease models using induced pluripotent stem cells to pursue two new antibody programs targeting the Tau protein and the Complement pathway, routes that could lead to new therapies for Alzheimer's and other neurodegenerative ailments.
Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.
As a startup, iPierian boasted some of the world's top experts on stem cells. The impeccable scientific pedigree, however, never translated into the kind of partnering deals the biotech was looking
Xconomy's Luke Timmerman has learned the board of hot stem cell start-up iPierian has dismissed much of its senior staff, including CEO Michael Venuti and "executives in charge of finance, business
In a single stroke iPierian has struck a deal to pool its IP on induced pluripotent stem cell technology with Kyoto University and signed on one of the most recognizable names in the field to its
Anyone who has experience in drug development knows how unreliable preclinical animal studies can be. After a therapy has pushed on into Phase II and Phase III, investigators commonly stumble across